• Users Online: 545
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2019  |  Volume : 6  |  Issue : 4  |  Page : 439-445

Does pregabalin reduce the sevoflurane requirement during laparoscopic cholecystectomy?


Department of Anaesthesia and Surgical ICU, College of Medicine, Mansoura University, Mansoura, Egypt

Correspondence Address:
MD Doaa G Diab
Department of Anaesthesia and Intensive Care, College of Medicine, Mansoura University, Mansoura, 35516
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/roaic.roaic_53_19

Rights and Permissions

Background Preoperative administration of pregabalin reduces the end-tidal concentrations of sevoflurane (ET-Sevo) during laparoscopic cholecystectomy with the added benefit of improving the quality of postoperative analgesia. Patients and methods After ethical approval, 43 patients scheduled for laparoscopic cholecystectomy were randomly allocated to receive placebo or 150 or 300 mg of pregabalin, 1 h before induction. Anaesthesia was maintained with 0.5–1.5 minimum alveolar concentration of sevoflurane, to maintain bispectral index at 50–60, with supplemental fentanyl and vecuronium. Changes in heart rate, mean blood pressure, ET-Sevo, quality of extubation and postoperative sedation scores, morphine consumptions and pain scores were recorded. Results After induction, compared with placebo and pregabalin 150 mg groups, patients receiving pregabalin 300 mg had smaller increases in heart rate (P<0.01), lower ET-Sevo (−45.5 and −42.9%, respectively) (P<0.001), better quality of extubation (P<0.001), higher sedation scores for first 8 postoperative hours (P<0.001), longer time to the first request of morphine (P<0.001), less morphine consumption (P<0.02) and lower pain scores (P<0.001) for the first 24 h after surgery. Conclusion Preoperative administration of pregabalin 300 mg is effective in reduction of the ET-Sevo during laparoscopic cholecystectomy without noted significant adverse effects.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed184    
    Printed10    
    Emailed0    
    PDF Downloaded34    
    Comments [Add]    

Recommend this journal